Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pro.med.cs praha a.s., Česká republika - trospium - 73 - spasmolytica

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

pro.med.cs praha a.s., Česká republika - trospium - 73 - spasmolytica

Európska únia - slovenčina - EMA (European Medicines Agency)

biopartners gmbh - somatropín - rast - pituitary and hypothalamic hormones and analogues, somatropin and somatropin agonists - somatropín biopartners je indikovaný na substitučnú liečbu endogénneho rastového hormónu u dospelých s deficitom rastového hormónu detstva alebo dospelosti (ghd). dospelý-nástup: u pacientov s ghd v dospelosti sú definované ako pacientov so známym hypotalamus-hypofýza patológia a aspoň jeden ďalší známy nedostatok a hypofýzy hormónu prolaktínu s výnimkou. títo pacienti by mali podstúpiť jednej dynamickej skúške s cieľom diagnostikovať alebo vylúčiť ghd. detstvo-nástup: u pacientov s detstva-nástup izolované ghd (žiadne dôkazy hypotalamus-hypofýza choroby alebo lebečnej ožiareniu), dve dynamické testy by mali byť vykonávané po ukončení rastu, s výnimkou tých, ktoré majú nízky inzulín-ako-rastový faktor-i (igf-i) koncentrácie (< -2 štandard-odchýlka skóre (kbÚ)), ktorý môže byť považovaný za jeden test. cut-off point dynamického testu by mali byť prísne.

Európska únia - slovenčina - EMA (European Medicines Agency)

ipsen pharma - somatropín - turner syndrome; dwarfism, pituitary - hypofýzové a hypotalamické hormóny a analógy - dlhodobá liečba detí s poruchou rastu v dôsledku nedostatočnej sekrécie endogénneho rastového hormónu. dlhodobá liečba rast poruchy súvisiace s turner syndrome. liečba prepubertal detí s poruchou rastu spojené s chronickou nedostatočnosťou obličiek až do doby transplantácie obličiek. výmena vnútorného rastového hormónu u dospelých pacientov s nedostatočnosťou rastového hormónu buď dieťa alebo dospelý-počiatok etiológie. nedostatočnosťou rastového hormónu by mali byť potvrdená zodpovedajúcim spôsobom pred zahájením liečby.

Európska únia - slovenčina - EMA (European Medicines Agency)

billev pharma aps - lutetium (177lu) chloride - radionuklidové zobrazovanie - terapeutické rádiofarmaká - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.

Európska únia - slovenčina - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, typ 2 - lieky používané pri cukrovke - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. trojlôžkových kombinovaná liečba) ako doplnok stravy a cvičenia pacientov nedostatočne kontrolované na ich maximálna tolerovaná dávka metformín a sulfonylmocoviny. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Európska únia - slovenčina - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, typ 2 - lieky používané pri cukrovke - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 a 5. 1 pre dostupné údaje o rôznych kombináciách).

Európska únia - slovenčina - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, typ 2 - lieky používané pri cukrovke - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. trojlôžkových kombinovaná liečba) ako doplnok stravy a cvičenia pacientov nedostatočne kontrolované na ich maximálna tolerovaná dávka metformín a sulfonylmocoviny. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Európska únia - slovenčina - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, typ 2 - lieky používané pri cukrovke - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. trojlôžkových kombinovaná liečba) ako doplnok stravy a cvičenia pacientov nedostatočne kontrolované na ich maximálna tolerovaná dávka metformín a sulfonylmocoviny. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Slovensko - slovenčina - ŠÚKL (Štátny ústav pre kontrolu liečiv)

novo nordisk a/s, dánsko - somatropín - 56 - hormona (lieČiva s hormonÁlnou aktivitou)